Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

400 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Heart rate prediction of outcome in heart failure following myocardial infarction depend on heart rhythm status an analysis from the high-risk myocardial infarction database initiative.
Agewall S, Tjessem LH, Rossignol P, Zannad F, Atar D, Lamiral Z, Machu JL, Dickstein K, Kjekshus J, von Lueder TG, Girerd N; High Risk Myocardial Infarction Database Initiative investigators. Agewall S, et al. Among authors: girerd n. Int J Cardiol. 2017 Dec 15;249:274-281. doi: 10.1016/j.ijcard.2017.09.182. Epub 2017 Sep 24. Int J Cardiol. 2017. PMID: 28964557
Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial.
Girerd N, Pang PS, Swedberg K, Fought A, Kwasny MJ, Subacius H, Konstam MA, Maggioni A, Gheorghiade M, Zannad F; EVEREST investigators. Girerd N, et al. Eur J Heart Fail. 2013 Nov;15(11):1228-35. doi: 10.1093/eurjhf/hft100. Epub 2013 Jun 19. Eur J Heart Fail. 2013. PMID: 23787720 Free article.
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Messig M, Vincent J, Girerd N, Bakris G, Pitt B, Zannad F. Rossignol P, et al. Among authors: girerd n. Circ Heart Fail. 2014 Jan;7(1):51-8. doi: 10.1161/CIRCHEARTFAILURE.113.000792. Epub 2013 Dec 2. Circ Heart Fail. 2014. PMID: 24297687 Clinical Trial.
Fibrinolysis for intermediate-risk pulmonary embolism.
Girerd N, Rossignol P, Zannad F. Girerd N, et al. N Engl J Med. 2014 Aug 7;371(6):579. doi: 10.1056/NEJMc1406283. N Engl J Med. 2014. PMID: 25099592 Free article. No abstract available.
Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials.
Rossignol P, Masson S, Barlera S, Girerd N, Castelnovo A, Zannad F, Clemenza F, Tognoni G, Anand IS, Cohn JN, Anker SD, Tavazzi L, Latini R; GISSI-HF and Val-HeFT Investigators. Rossignol P, et al. Among authors: girerd n. Eur J Heart Fail. 2015 Apr;17(4):424-33. doi: 10.1002/ejhf.240. Epub 2015 Feb 22. Eur J Heart Fail. 2015. PMID: 25704364 Free article.
400 results